How do privacy and public-safety rules affect the cost and length of clinical testing?

In the field of translational medicine, regulatory burdens designed to protect public safety and individual privacy are essential components of the biomedical enterprise. However, as the thresholds for these safety and privacy protections are raised, the complexity, length, and cost of clinical testing increase accordingly.1

These requirements are necessary to ensure ethical standards and participant protection, but they contribute to the significant financial and temporal challenges inherent in bringing new therapies to market. Furthermore, the increasing sophistication of modern biotechnology has led to more complex therapeutic agents—such as those involving genetic modification or cellular substances—which are more difficult to validate. Because these agents often act through distinct, sometimes poorly understood mechanisms, standardizing safety and efficacy evaluations becomes more complicated, further impacting the duration and expense of the clinical trial process.1